We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
-1.1%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$8.53B
AUM Growth
+$93.1M
(+1.1%)
Cap. Flow
+$472M
Cap. Flow
% of AUM
5.53%
Top 10 Holdings %
Top 10 Hldgs %
16.89%
Holding
812
New
193
Increased
197
Reduced
149
Closed
231
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Analog Devices
ADI
|
+$188M |
| 2 |
AbbVie
ABBV
|
+$121M |
| 3 |
Electronic Arts
EA
|
+$112M |
| 4 |
Autodesk
ADSK
|
+$97.3M |
| 5 |
Keysight
KEYS
|
+$92.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HES
Hess
HES
|
+$123M |
| 2 |
Amphenol
APH
|
+$113M |
| 3 |
Cencora
COR
|
+$108M |
| 4 |
Microsoft
MSFT
|
+$104M |
| 5 |
HP
HPQ
|
+$91.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.52% |
| 2 | Technology | 26.19% |
| 3 | Industrials | 9.44% |
| 4 | Energy | 7.95% |
| 5 | Consumer Discretionary | 5.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Tyra Biosciences
TYRA
$1.59B
| $5.65M | 0.07% |
410,435
| – | – |
|
302
lululemon athletica
LULU
$14.2B
| $5.53M | 0.06% |
14,348
+10,516
| +274% | +$4.02M |
|
303
Enliven Therapeutics
ELVN
$4.34B
| $5.41M | 0.06% |
+395,686
| New | +$6.66M |
|
304
Bausch + Lomb
BLCO
$5.9B
| $5.25M | 0.06% |
309,491
-523,019
| -63% | -$9.78M |
|
305
Coty
COTY
$2.45B
| $5.21M | 0.06% |
+474,668
| New | +$5.59M |
|
|
MRNS
306
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $5.08M | 0.06% |
631,520
-168,480
| -21% | -$1.4M |
|
307
Replimune Group
REPL
$1B
| $5.02M | 0.06% |
293,622
+18,621
| +7% | +$366K |
|
|
RYZB
308
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $5M | 0.06% |
+225,000
| New | +$4.72M |
|
|
FNA
309
DELISTED
Paragon 28, Inc.
FNA
| $4.92M | 0.06% |
392,264
+198,283
| +102% | +$2.99M |
|
310
Xenon Pharmaceuticals
XENE
$6.21B
| $4.9M | 0.06% |
143,451
-146,949
| -51% | -$5.5M |
|
|
SABA
311
Saba Capital Income & Opportunities Fund II
SABA
$223M
| $4.8M | 0.06% |
621,739
+584,431
| +1,567% | +$4.8M |
|
312
Woodward
WWD
$21.7B
| $4.77M | 0.06% |
38,413
-11,984
| -24% | -$1.5M |
|
313
Corning
GLW
$137B
| $4.76M | 0.06% |
+156,218
| New | +$5.11M |
|
314
Tenet Healthcare
THC
$20.9B
| $4.73M | 0.06% |
+71,830
| New | +$5.37M |
|
315
Biomea Fusion
BMEA
$91.8M
| $4.7M | 0.06% |
341,673
| – | – |
|
|
ODP
316
DELISTED
ODP
ODP
| $4.69M | 0.06% |
101,681
+23,241
| +30% | +$1.12M |
|
|
FDEU
317
DELISTED
First Trust Dynamic Europe Equity Income Fund
FDEU
| $4.65M | 0.05% |
374,816
| – | – |
|
318
Sweetgreen
SG
$703M
| $4.62M | 0.05% |
392,960
+150,080
| +62% | +$2.09M |
|
319
Pegasystems
PEGA
$5.18B
| $4.56M | 0.05% |
+210,232
| New | +$5.14M |
|
320
CRISPR Therapeutics
CRSP
$5.04B
| $4.56M | 0.05% |
100,412
+50,412
| +101% | +$2.6M |
|
321
Levi Strauss
LEVI
$9.48B
| $4.55M | 0.05% |
335,302
+212,282
| +173% | +$2.97M |
|
322
ManpowerGroup
MAN
$2.55B
| $4.51M | 0.05% |
61,521
+37,736
| +159% | +$2.94M |
|
|
PRO
323
DELISTED
PROS Holdings
PRO
| $4.51M | 0.05% |
130,165
-36,727
| -22% | -$1.27M |
|
324
Crinetics Pharmaceuticals
CRNX
$8.92B
| $4.46M | 0.05% |
+150,000
| New | +$3.09M |
|
|
KLRS
325
Kalaris Therapeutics
KLRS
$102M
| $4.44M | 0.05% |
89,855
+14,724
| +20% | +$1M |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q3 2023 Portfolio in Review
As of Q3 2023, Woodline Partners held 812 positions worth $8.53B, up 1.1% from $8.44B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Woodline Partners deployed $472M of net new capital in Q3 2023, opening 193 new positions and adding to 197 existing holdings. Its largest new stake was Analog Devices: 1,016,972 shares worth $178M.
By sector, the portfolio is most concentrated in Healthcare at 39% of assets, up from 38% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Hess, an estimated $123M trimmed.
- Woodline Partners's largest Q3 2023 buy was Analog Devices: 1,016,972 shares worth $178M.
- Woodline Partners added most to AbbVie in Q3 2023, an estimated $121M increase.
- Woodline Partners's biggest Q3 2023 reduction was Hess, cutting an estimated $123M.
- Woodline Partners fully exited HP in Q3 2023, selling an estimated $91.2M.
- Woodline Partners's ten largest holdings make up 17% of its $8.53B portfolio in Q3 2023.
- Woodline Partners opened 193 new positions and closed 231 in Q3 2023.
- Woodline Partners's portfolio value rose 1.1% quarter-over-quarter to $8.53B.
Based on Woodline Partners's 13F filing for Q3 2023, filed 14 Nov 2023.